Estimated dates are subject to change due to patent litigation, additional patents, exclusivities Estimated Dates of Possible First

Time Generic/ Rx-to-OTC Market Entry Year Period 1Q (Jan) 1Q (Mar) 1Q (Mar) 1Q (Mar) 1Q (Mar) 1Q (Mar) 1Q (Mar) 1Q (Mar) 1Q (Mar) 2Q (Apr) 2Q (May) 2Q (May) 2Q (Jun) 3Q (Jul) 3Q (Jul) 3Q (Aug) 3Q (Aug) 3Q (Aug) 3Q (Sep) Brand Name Symbyax Geodon Lexapro1 Seroquel Avandia Avandamet Avandaryl Avapro Avalide Provigil Plavix3 Viramune Lescol and Lescol XL Tricor Clarinex & Clarinex-D
(planning OTC prior to generic 2 availability)

Generic name

Common use(s) Treatment-resistant depression, depression in Bipolar I Disorder Schizophrenia, bipolar disorder Depression, anxiety Schizophrenia, bipolar disorder Type 2 diabetes Type 2 diabetes Type 2 diabetes High blood pressure High blood pressure Excessive sleepiness Prevent blood clots HIV infection High cholesterol High cholesterol

2010 US Retail Sales: (in millions)^ $89 $1,059 $2,591 $3,549 $286 $161 $35 $398 $341 $1,014 $5,020 $108 Lescol: $26 Lescol XL: $67 $1,123

2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012 2012

olanzapine/fluoxetine ziprasidone escitalopram quetiapine rosiglitazone rosiglitazone/ metformin glimepiride/ rosiglitazone irbesartan irbesartan/ hydrochlorothiazide modafinil clopidogrel
(approved 1/06 and briefly launched 8/06)

nevirapine fluvastatin fenofibrate desloratadine and desloratadine/ pseudoephedrine montelukast pioglitazone levalbuterol inhalation solution sildenafil

2012

Allergy symptoms, hives Asthma, allergy symptoms Type 2 diabetes Asthma, COPD Pulmonary arterial hypertension

Clarinex: $177 Clarinex D: $32

2012 2012 2012 2012

Singulair Actos Xopenex (not HFA)4 Revatio

$3,824 $2,914 $415 $178

Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities 2010 US Retail Sales: (in millions)^ Diovan: $1,585 Diovan HCT: $1,431 $46 $1,066 Atacand: $122 Atacand HCT: $59 $41 Maxalt: $278 Maxalt-MLT: $232 $431

Year 2012 2012 2012 2012 2012 2012 2012

Period 3Q (Sep) 3Q (Sep) 4Q (Nov) 4Q (Dec) 4Q (Dec) 4Q (Dec) 4Q (Dec) 1Q (Jan)

Brand Name Diovan and Diovan HCT5 Detrol Lidoderm Atacand and Atacand HCT Evoxac Maxalt and Maxalt-MLT Actoplus Met

Generic name valsartan and valsartan/ hydrochlorothiazide tolterodine lidocaine topical patch candesartan and candesartan/ hydrochlorothiazide cevimeline rizatriptan pioglitazone/ metformin oxymorphone extended-release tablet
(previously approved, not launched 6/10)

Common use(s) High blood pressure Overactive bladder Pain due to postherpetic neuralgia High blood pressure Sjgren's syndrome Migraines Type 2 diabetes

2013

Opana ER

Pain Hypercalcemia of malignancy, reduce bone complications from cancer Viral infections Migraines Osteoporosis Amyotrophic lateral sclerosis Glioblastoma multiforme Gaucher Disease High cholesterol High cholesterol GERD

$405

2013

1Q (Mar) 1Q (Mar) 2Q (May) 2Q (Jun) 2Q (Jun) 3Q (Aug) 3Q (Aug) 3Q (Sep) 3Q (Sep) 4Q (Nov)

Zometa

zoledronic acid injection

$5

2013 2013 2013 2013

Valcyte Zomig Fosamax Plus D Rilutek Temodar6 Cerezyme Niaspan Advicor AcipHex

valganciclovir zolmitriptan alendronate / cholecalciferol riluzole

(generic approved, not launched 1/03)

$195 $141 $59 $36

temozolomide
(generic approved, not launched 3/10)

2013 2013 2013 2013 2013

$189 $1 $889 $55 $1,007

imiglucerase injection niacin extended-release tablet lovastatin/niacin rabeprazole

(tablets approved but not launched 2/07)

Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities 2010 US Retail Sales: (in millions)^ $198 $2,891 $139 Micardis: $253 Micardis HCT: $218 $633 $577 $490 $406 $1,360 $522 $51 $5,586 $1,497 $818 NA $1 $663 $290 $123 (cream and gel) $1,108

Year 2013 2013 2014 2014 2014 2014 2014 2014 2014 2014 2014 2014 2014 2014 2014 2014 2014 2014 2014 2014

Period 4Q (Dec) 4Q (Dec) 1Q (Jan) 1Q (Jan) 1Q (Jan) 1Q (Jan) 1Q (Jan) 1Q (Feb) 1Q (Feb) 1Q (Mar) 2Q (Apr) 2Q (May) 2Q (May) 2Q (May) 2Q (May) 2Q (Jun) 2Q (Jun) 2Q (Jun) 2Q (Jun) 3Q (Jul)

Brand Name Vivelle-DOT Cymbalta Rapamune Micardis and Micardis HCT Loestrin 24 Fe7 Asacol Trilipix Avelox Enbrel Evista Viracept Nexium Celebrex Lunesta Lupron 3.75 mg Actonel with calcium Actonel8 Xeloda Tazorac gel Nasonex

Generic name estradiol extendedrelease film duloxetine sirolimus telmisartan and telmisartan/ hydrochlorothiazide ethinyl estradiol/ norethindrone mesalamine delayedrelease tablet fenofibric acid moxifloxacin etanercept injection raloxifene nelfinavir esomeprazole celecoxib eszopiclone leuprolide injection risedronate/calcium risedronate capecitabine Tazarotene gel mometasone nasal spray

Common use(s) Menopausal symptoms Depression, anxiety, nerve/musculoskeletal pain, fibromyalgia Prevent organ rejection High blood pressure Contraception Ulcerative colitis High cholesterol Bacterial infections Rheumatoid arthritis, JIA, plaque psoriasis, ankylosing spondylitis Osteoporosis, reduce risk of breast cancer HIV infection GERD, ulcers Pain Insomnia Endometriosis, fibroids Osteoporosis Osteoporosis Colorectal, breast cancers Acne Allergic rhinitis

Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities 2010 US Retail Sales: (in millions)^ $303 $171 $155 $439 $40 $386 $796 $30 $73 $150 $295 $806 $796 (all formulations) $23 $4,077 $253 $486 $15 $208 $332

Year 2014 2014 2014 2014 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015

Period 3Q (Aug) 3Q (Sep) 4Q (Oct) 4Q (Nov) 1Q (Jan) 1Q (Jan) 1Q (Jan) 1Q (Feb) 1Q (Mar) 1Q (Mar) 1Q (Mar) 1Q (Mar) 2Q (Apr) 2Q (Apr) 2Q (Apr) 2Q (May) 2Q (May) 2Q (May) 2Q (May) 2Q (Jun)

Brand Name Lumigan Renagel TOBI Copaxone Cipro HC Norvir Namenda Tarka Hepsera Sustiva Renvela Lovaza Namenda Oxytrol Abilify Zyvox Avodart Epogen Procrit WelChol

Generic name bimatoprost ophthalmic solution sevelamer tobramycin inhalation glatiramer injection ciprofloxacin/ hydrocortisone otic suspension ritonavir memantine
(generic approved 4/14/10, not launched)

Common use(s) Glaucoma, ocular hypertension Chronic kidney disease P. aeruginosa infection in cystic fibrosis Multiple sclerosis Bacterial external and middle ear infections HIV infection Alzheimers disease High blood pressure Chronic hepatitis B HIV infection Chronic kidney disease High triglycerides Alzheimers disease Overactive bladder Schizophrenia, bipolar disorder, autistic disorder, depression Bacterial infections Benign prostatic hyperplasia Anemia Anemia High cholesterol

trandolapril/verapamil adefovir dipivoxil efavirenz sevelamer omega-3-acid ethyl esters memantine oral solution oxybutynin extendedrelease film aripiprazole linezolid dutasteride epoetin alfa injection epoetin alfa injection colesevelam

Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities 2010 US Retail Sales: (in millions)^ Travatan: $73 Travatan Z: $298 $288

Year 2015 2015

Period 2Q (Jun) 3Q (Jul) 3Q (Jul) 3Q (Jul) 3Q (Aug) 3Q (Sep) 4Q (Oct) 4Q (Oct) 4Q (Oct) 4Q (Dec) 4Q (Dec) 4Q (Dec) 4Q (Dec) 4Q (Dec) 4Q (Dec) 4Q (Dec) 1Q (Mar) 2Q (May) 2Q (Jun)

Brand Name Travatan and Travatan Z Aggrenox9

Generic name travoprost ophthalmic solution aspirin/dipyridamole extended-release capsule imatinib dornase alfa inhalation solution testosterone gel guanfacine extendedrelease tablets palonosetron pegfilgrastim injection palivizumab injection olopatadine ophthalmic solution olopatadine ophthalmic solution albuterol/ipratropium inhalation enfuvirtide injection carvedilol extendedrelease capsules ethinyl estradiol/ norgestimate eprosartan 400 mg tablet abacavir/lamivudine tablets ethinyl estradiol/ norelgestromin transdermal system dexmethylphenidate extended-release capsule

Common use(s) Glaucoma, ocular hypertension Prevent blood clots Chronic myeloid leukemia, gastrointestinal stromal tumors Cystic fibrosis Low testosterone ADHD Nausea, vomiting Neutropenia Respiratory syncytial virus Allergic conjunctivitis Allergic conjunctivitis COPD HIV infection High blood pressure Contraception High blood pressure HIV infection Contraception

2015

Gleevec

$603

2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2015 2016 2016

Pulmozyme AndroGel Intuniv Aloxi Neulasta Synagis Pataday Patanol Combivent Fuzeon Coreg CR Ortho Tri-Cyclen Lo Teveten Epzicom tablets Ortho Evra

$176 $761 $175 $1 $94 $4 $233 $251 $738 $17 $261 $400 Teveten (all strengths): $5 $349 $138

2016

Focalin XR

ADHD

$496

Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities 2010 US Retail Sales: (in millions)^ $223 $3,277 $10 Benicar: $620 Benicar HCT: $569 $9 $195 (all strengths) $765 $112 $321 $1,060

Year 2016 2016 2016 2016 2016 2016 2016 2016 2016 2016

Period 2Q (Jun) 3Q (Jul) 3Q (Sep) 4Q (Oct) 4Q (Oct) 4Q (Oct) 4Q (Nov) 4Q (Dec) 4Q (Dec) 4Q (Dec) 4Q (Dec) 4Q (Dec) 1Q (Jan) 2Q (Apr) 2Q (May) 2Q (May) 2Q (Jun) 2Q (Jun) 3Q (Sep)

Brand Name Enablex Crestor Rituxan Benicar & Benicar HCT Spectracef Azor Seroquel XR Lupron Kaletra Zetia

Generic name darifenacin extendedrelease tablets rosuvastatin calcium rituximab injection olmesartan & olmesartan/ hydrochlorothiazide cefditoren pivoxil amlodipine 10mg/ olmesartan 20mg quetiapine extendedrelease tablets leuprolide injection lopinavir/ritonavir tablet ezetimibe

Common use(s) Overactive bladder High cholesterol Rheumatoid arthritis, NHL, CLL High blood pressure Bacterial infections High blood pressure Schizophrenia, depression, bipolar disorder Advanced prostate cancer HIV infection High cholesterol Rheumatoid arthritis, JIA, ankylosing spondylitis, Crohns disease, plaque psoriasis HIV infection Acromegaly, carcinoid syndrome High cholesterol Multiple myeloma, lymphoma ADHD Migraines Influenza Fungal infections

2016

Humira

adalimumab injection

$1,205

2016 2017 2017 2017 2017 2017 2017 2017

Norvir Sandostatin Vytorin Velcade Strattera Relpax Tamiflu Cancidas

ritonavir 100 mg tablets octreotide injection ezetimibe/simvastatin bortezomib injection atomoxetine eletriptan oseltamivir capsules caspofungin injection

$386 (all strengths) $33 $1,034 $4 $533 $233 $124 $0.2

Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities 2010 US Retail Sales: (in millions)^ $8 $286 $63 (all forms) $335 $754 $1 $898 $24 $12 $385 $439 $0.5 $245 $2 $303 Tekturna: $147 Tekturna HCT: $38 $1 $1 $0.9 $12 $471

Year 2017 2017 2018 2018 2018 2018 2018 2018 2018 2018 2018 2018 2018 2018 2019 2019 2019 2019 2019 2019 2019

Period 4Q (Nov) 4Q (Dec) 1Q (Jan) 1Q (Jan) 2Q (May) 3Q (Jul) 3Q (Aug) 3Q (Sep) 3Q (Sep) 3Q (Sep) 4Q (Oct) 4Q (Nov) 4Q (Nov) 4Q (Dec) 1Q (Jan) 1Q (Jan) 1Q (Feb) 1Q (Feb) 2Q (Apr) 2Q (Apr) 2Q (May)

Brand Name Adcirca Exforge Follistim Viread Cialis Letairis Solodyn ER Remicade Nitrostat Sensipar NuvaRing Tyvaso Tarceva Xolair Exelon Patch Tekturna and Tekturna HCT Gilenya Advate BeneFIX Exjade Vesicare

Generic name tadalafil amlodipine/valsartan follitropin beta vial tenofovir 300 mg tablet tadalafil ambrisentan minocycline extendedrelease tablets infliximab injection nitroglycerin sublingual tablets cinacalcet ethinyl estradiol/ etonogestrel vaginal ring treprostinil inhalation solution erlotinib omalizumab injection rivastigmine extendedrelease film aliskiren and aliskiren/ hydrochlorothiazide fingolimod antihemophilic factor, recombinant coagulation factor IX, recombinant deferasirox solifenacin

Common use(s) Pulmonary arterial hypertension High blood pressure Infertility Chronic hepatitis B infection Erectile dysfunction Pulmonary arterial hypertension Acne Rheumatoid arthritis, Crohns disease, plaque psoriasis Angina Hyperparathyroidism, hypercalcemia Contraception Pulmonary arterial hypertension Non-small cell lung cancer Allergic asthma Alzheimers disease High blood pressure Multiple sclerosis Hemophilia A Hemophilia B Chronic iron overload Overactive bladder

Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities 2010 US Retail Sales: (in millions)^ $665 $1,571 $63 (all forms) $5 $112 $193 NA $18 $289 $244 $1,011 $643 $252 $290 $505 $15 $425 $321 $24 $7

Year 2019 2019 2019 2019 2019 2019 2019 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2021 2021

Period 2Q (Jun) 2Q (Jun) 3Q (Aug) 4Q (Oct) 4Q (Oct) 4Q (Nov) 4Q (Dec) 1Q (Jan) 1Q (Mar) 2Q (Apr) 2Q (Apr) 2Q (May) 2Q (Jun) 2Q (Jun) 3Q (Jul) 3Q (Sep) 4Q (Nov) 4Q (Nov) 2Q (May) 3Q (Aug)

Brand Name Reyataz Lyrica Follistim Orencia Revlimid Pegasys Zytiga Nexavar Vigamox Bystolic Viagra Detrol LA Dexilant Lialda Byetta Tykerb Chantix Kaletra Zomig spray Crixivan

Generic name atazanavir pregabalin follitropin beta cartridge abatacept injection lenalidomide peginterferon alfa-2a injection abiraterone sorafenib moxifloxacin ophthalmic solution nebivolol sildenafil tolterodine dexlansoprazole delayed-release capsule mesalamine delayedrelease tablet exenatide injection lapatinib varenicline lopinavir/ritonavir oral solution zolmitriptan nasal spray indinavir

Common use(s) HIV infection Fibromyalgia, nerve pain, seizures Infertility Rheumatoid arthritis Multiple myeloma, myelodysplastic syndromes Chronic hepatitis B, Chronic hepatitis C Prostate cancer Renal cell cancer, liver cancer Bacterial conjunctivitis High blood pressure Erectile dysfunction Overactive bladder GERD, erosive esophagitis Ulcerative colitis Type 2 diabetes Breast cancer Smoking cessation HIV infection Migraines HIV infection

Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities 2010 US Retail Sales: (in millions)^ $109 $1,268 $155 $258 $194 NA $563 $1,078 $964 $37 $117 $51 $0.028 NA $1 $98 $329 $164 $152 $543

Year

Period 3Q (Aug) 3Q (Sep) 1Q (Jan) 2Q (Apr) 3Q (Aug) 1Q (Mar) 2Q (May) 2Q (Jun) 3Q (Sep) 3Q (Sep) 4Q (Dec) 1Q (Feb) 2Q (Jun) 4Q (Nov) 1Q (Jan) 1Q (Mar) 3Q (Sep) 3Q (Sep) 3Q (Sep) 4Q (Oct)

Brand Name

Generic name

Common use(s) Renal cell carcinoma, GIST, pancreatic neuroendocrine tumors HIV infection Glaucoma, ocular hypertension Rosacea Type 2 diabetes Acne Osteoporosis ADHD Asthma Plaque psoriasis Multiple myeloma, erythema nodosum leprosum Rheumatoid arthritis, Crohns disease Narcolepsy Phenylketonuria Multiple sclerosis Rheumatoid arthritis Multiple sclerosis Multiple sclerosis Multiple sclerosis Type 2 diabetes

2021 2021 2022 2022 2022 2023 2023 2023 2023 2023 2023 2024 2024 2025 2026 2026 2026 2026 2026 2026

Sutent Truvada Alphagan P Oracea Victoza Differin Boniva Vyvanse Proair HFA Stelara Thalomid Cimzia Xyrem Kuvan Ampyra Simponi Avonex Administration Pack Betaseron Rebif Janumet

sunitinib tenofovir/emtricitabine brimonidine ophthalmic solution doxycycline liraglutide injection adapalene 0.3% gel ibandronate lisdexamfetamine albuterol inhalation ustekinumab injection thalidomide certolizumab injection sodium oxybate 500 mg/mL oral solution sapropterin dalfampridine extended-release tablets golimumab injection interferon beta-1a injection interferon beta-1b injection interferon beta-1a injection metformin/sitagliptin

Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities 2010 US Retail Sales: (in millions)^ $1,434 $1,703

Year 2026 2027

Period 4Q (Oct) 1Q (Mar)

Brand Name Januvia Spiriva

Generic name sitagliptin tiotropium powder for inhalation

Common use(s) Type 2 diabetes COPD

^ Dollar amount reflects combined sales of all strengths and formulations of the product, unless otherwise indicated; source IMS Health

Lexapros '712 patent was originally slated to expire in December 2009, which included an additional six months of pediatric exclusivity. The U.S. Patent & Trademark Office granted the patent an 828-day extension in March 2006. Therefore, the estimated date for generic availability changed to March 2012. A recent patent litigation decision has also sided with Forest, upholding the validity of a key patent on Lexapro and keeping generics off the market until patent expiration in 2012. 2 Several companies have announced the settlement of patent litigation relating to Desloratadine Tablets, 5 mg (Clarinex). Pursuant to these settlements, the generic manufacturers will have the right to market Desloratadine Tablets, 5 mg, in the U.S. on July 1, 2012, or earlier in certain circumstances. Clarinex and Clarinex D will likely be switched to OTC availability prior to generic availability. 3 Generic Plavix was approved 1/20/06 with paragraph IV certification giving Apotex 180-day exclusivity. Apotex launched their generic at risk on August 8, 2006. A preliminary injunction was granted on August 31, ordering Apotex to halt its sales of generic Plavix. The judge did not require Apotex to recall clopidogrel that had already been distributed. Bristol-Myers Squibb/Sanofis patent infringement trial against Apotex began January 22, 2007. 4 Mylan launched their first-time generic for Xopenex inhalation solution 0.25% with 180 day exclusivity in September 2009. In April 2008, Breath Limited received FDA approval for their generic Xopenex inhalation solution 0.021%, .0042%, and 0.0103%. Sepracor settled a patent dispute with them which will allow Breath to market generic versions of the drug beginning August 2012 with a 180-day exclusive license. In March 2009, Sepracor entered into a Settlement and License Agreement with Teva and Barr. The agreement permits Barr and Teva to launch generic versions of Xopenex inhalation solution dosages under terms of a non-exclusive license commencing on February 17, 2013. 5 Diovan received pediatric exclusivity, extending the drug's patent protection in the US until September 2012. 6 Patent litigation is ongoing between Teva and Merck with regard to Temodar. The U.S. Court of Appeals for the Federal Circuit court is reviewing an appeal by Merck. If the Appeals court agrees that Mercks patent for Temodar is unenforceable, Teva may launch their generic at any time. 7 Warner Chilcott sued Watson for patent infringement on Loestrin 24 FE in 2006. A settlement was reached in January 2009. Warner Chilcott sued Lupin for patent infringement on Loestrin 24 FE in September 2009. 8 In October 2007, Teva received FDA approval of its ANDA for Actonel 5 mg, 30 mg, and 35 mg tablets but did not launch due to ongoing patent litigation. In February 2008, the U.S. District Court for the District of Delaware found Procter & Gambles U.S. Patent No. 5,538,122 covering Actonel to be valid. Teva intends to appeal this decision. Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities Boehringer Ingelheim sued Teva/Barr for patent infringement on Aggrenox in July 2007. The companies announced a settlement agreement in August 2008. Note: Pulmicort dry powder inhalation and Advair have been removed from the table. These both contain inhaled corticosteroids, and the FDA has not determined a standard for bioequivalence for inhaled corticosteroids in multi-dose inhalers (MDIs) or dry powder inhalers (DPIs). Therefore, generic availability may be significantly delayed. At this time, there is no estimated date of generic approval.
9

Information current as of January 2012. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities
Medco is a registered trademark of Medco Health Solutions, Inc. 2012 Medco Health Solutions, Inc. All rights reserved.